<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03780517</url>
  </required_header>
  <id_info>
    <org_study_id>BOS172738-01</org_study_id>
    <secondary_id>2018-002612-27</secondary_id>
    <nct_id>NCT03780517</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors</brief_title>
  <official_title>A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to assess the safety and tolerability of BOS172738 when&#xD;
      administered to patients with advanced solid tumors with rearranged during transfection (RET)&#xD;
      gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended&#xD;
      phase 2 dose (RP2D) of BOS172738.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with any treatment-emergent (TE) serious adverse event (SAE)</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any non-serious TEAE</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with grade 3, grade 4, or grade 5 TEAEs</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any related TEAE</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any TEAE leading to study drug discontinuation</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BOS172738</measure>
    <time_frame>throughout Cycle 1 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase 2 dose (RP2D) of BOS172738</measure>
    <time_frame>28-day cycles in Part A (minimum of one dose of BOS172738 received)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Disease Control Rate (ODCR)</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete Response (DoCR)</measure>
    <time_frame>a minimum of approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Plasma concentration of BOS172738</measure>
    <time_frame>Pre-dose on Days 1, 2, 15, and 16 of Cycle 1; Day 1 of Cycles 2, 3, and 4. 15 minutes (min); 30 min; 1, 3, 6, 8, 10, and 12 hours after the BOS1722722 dose on Days 1 and 15 of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Plasma concentration of BOS172738</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 2, 3, and 4 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Advanced Nonhaematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>BOS172738</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A (dose escalation), participants with advanced solid tumors with rearranged during transfection (RET) gene alterations will receive oral BOS172738 at a starting dose of 10 milligrams (mg) once daily in each 28-day cycle. In Part B (dose expansion), participants with RET gene-fusion non-small cell lung cancer (NSCLC), with RET gene-mutant medullary thyroid cancer (MTC), and with RET gene-altered advanced tumors or NSCLC/MTC with prior specific RET gene-targeted therapy will be enrolled in Cohorts 1, 2, and 3, respectively, and will receive oral BOS172738 once daily in each 28-day cycle at the recommended Phase 2 dose (RP2D) established in Part A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOS172738</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>BOS172738</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants are eligible to be included in the study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
          -  Male or female participants must be ≥ 18 years, at the time of signing the informed&#xD;
             consent&#xD;
&#xD;
          -  Diagnosis of advanced solid tumor with a documented rearranged during transfection&#xD;
             (RET) gene altered malignancy as determined locally by a DNA based assay of tumor&#xD;
             tissue and/or blood&#xD;
&#xD;
          -  Participants must have no alternative approved therapy.&#xD;
&#xD;
          -  For participants in Part B expansion cohort only: documented local diagnosis of either&#xD;
             1) advanced RET gene fusion non-small cell lung cancer (NSCLC); 2) advanced RET gene&#xD;
             mutant medullary thyroid cancer (MTC); or 3) other RET gene altered advanced tumors or&#xD;
             NSCLC/MTC with prior specific RET gene targeted therapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Negative pregnancy test for females of child bearing potential; must be surgically&#xD;
             sterile, postmenopausal, or willing and able to be compliant with a contraceptive&#xD;
             regimen&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with local regulations.&#xD;
&#xD;
          -  Capable of giving signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          -  Inability to take oral medications or gastrointestinal (GI) conditions that can&#xD;
             interfere with the swallowing or absorption of study medication&#xD;
&#xD;
          -  Uncontrolled or severe concurrent medical condition&#xD;
&#xD;
          -  History of upper GI bleeding, ulceration, or perforation within 12 months prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  Known history of stroke or cerebrovascular accident within 6 months prior to the first&#xD;
             dose of study drug&#xD;
&#xD;
          -  Participants with known infection with human immunodeficiency virus (HIV) or Acquired&#xD;
             Immune Deficiency Syndrome (AIDS) (testing not required)&#xD;
&#xD;
          -  Participants who are hepatitis B surface antigen positive or participants who are&#xD;
             hepatitis C antibody positive (Participants who have been successfully treated for&#xD;
             hepatitis C virus [HCV] are eligible if an undetectable HCV viral load at least 6&#xD;
             months after completion of treatment can be demonstrated.)&#xD;
&#xD;
          -  Any evidence of serious active infections&#xD;
&#xD;
          -  Uncontrolled or severe cardiovascular disease&#xD;
&#xD;
          -  Uncontrolled intercurrent illness or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Participants with a prior or concurrent malignancy other than the malignancies under&#xD;
             study&#xD;
&#xD;
          -  Ongoing cancer directed therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Banner Health</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oncológico Dr. Rosell, S.L.</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Start Madrid - Ciocc</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START MADRID-FJD, Hospital Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BOS172738</keyword>
  <keyword>RET gene</keyword>
  <keyword>Medullary Thyroid Cancer</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

